Literature DB >> 27408183

Renal Transplantation: Experience at a Single Centre.

Msn Murty1, V K Saxena2, U K Sharma1, S Tandon3, P Sharma3.   

Abstract

BACKGROUND: Renal transplantation program in the Armed Forces commenced in Feb 1991 and till date 245 patients have undergone renal transplantation at INHS Asvini. We describe our protocols for donor and recipient evaluation and immunosuppression.
METHODS: 245 patients received renal transplants during this period, 243 (99.2%) being from live donors. Most of them were started on triple immunosuppression comprising of cyclosporine, azathioprine and prednisolone. Newer drugs like mycophenolate, tacrolimus and sirolimus were administered in a select population. RESULT: 69 (28.1%) of them had at least one episode of acute rejection, most of which were steroid responsive and 13 (18.8%) of them required either anti CD3 monoclonal or anti-thymocyte globulin (ATG). Complete recovery with normal renal function occurred in 54 (78.2%) cases and 15 (21.7%) recovered with residual dysfunction with maximum serum creatinine being 2.1mg/dl. There were three (1.2%) cases of accelerated rejection during the first week of transplantation and one had graft rupture. All three lost their grafts. There were eight (3.2%) cases of acute tubular necrosis, who recovered completely within 8-14 days. Immediate infections included wound sepsis, lower respiratory tract infection, disseminated candidiasis and disseminated aspergillosis. Late infections included pulmonary tuberculosis, disseminated tuberculosis, cytomegalovirus infection and recurrent urinary tract infection. 28 (11.4%) patients developed post transplant diabetes mellitus. At the end of one year and five years, graft and patient survival were 97.2%, 93%, 80.9% and 85.7% respectively.
CONCLUSION: Our outcomes show that the transplantation is a viable mode of renal replacement therapy in patients of end stage kidney disease with a near normal rehabilitation.

Entities:  

Keywords:  Complications; Immunosuppression; Kidney; Transplantation

Year:  2011        PMID: 27408183      PMCID: PMC4921442          DOI: 10.1016/S0377-1237(09)80047-6

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  16 in total

Review 1.  Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data.

Authors:  Angela C Webster; Rebecca C Woodroffe; Rod S Taylor; Jeremy R Chapman; Jonathan C Craig
Journal:  BMJ       Date:  2005-09-12

2.  Impact of hepatitis C virus infection in renal transplant recipients.

Authors:  A S Narula; A Hooda; A C Anand; S Patrikar
Journal:  Indian J Gastroenterol       Date:  2005 Jul-Aug

Review 3.  Infection in organ-transplant recipients.

Authors:  J A Fishman; R H Rubin
Journal:  N Engl J Med       Date:  1998-06-11       Impact factor: 91.245

4.  The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation.

Authors:  C G ter Meulen; J F Wetzels; L B Hilbrands
Journal:  Nephrol Dial Transplant       Date:  2000-05       Impact factor: 5.992

Review 5.  Living-donor kidney transplantation: a review of the current practices for the live donor.

Authors:  Connie L Davis; Francis L Delmonico
Journal:  J Am Soc Nephrol       Date:  2005-06-01       Impact factor: 10.121

6.  Look-up survival tables for living-donor renal transplants: OPTN/UNOS data 1995-2002.

Authors:  David W Gjertson
Journal:  Clin Transpl       Date:  2003

7.  Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.

Authors: 
Journal:  Lancet       Date:  1995-05-27       Impact factor: 79.321

8.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.

Authors: 
Journal:  Transplantation       Date:  1996-04-15       Impact factor: 4.939

9.  Triple therapy in cadaver renal transplantation.

Authors:  R M Jones; J A Murie; R D Allen; A Ting; P J Morris
Journal:  Br J Surg       Date:  1988-01       Impact factor: 6.939

10.  Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

Authors:  B Nashan; R Moore; P Amlot; A G Schmidt; K Abeywickrama; J P Soulillou
Journal:  Lancet       Date:  1997-10-25       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.